Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.
BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.
BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.
BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.
Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.
The report is neutral to bearish due to lack of recent insider buying and considerable selling action, indicating potential low confidence. High insider ownership might align incentives with other shareholders.
Here are some of the names moving in midday trading: $Datadog(DDOG.US)$ — Shares rallied more than 30% after the cloud company reported a third-quarter earnings and revenue beat before the bell. Datadog’s guidance for both earnings per share and revenue for the fourth quarter and the full year also exceeded expectations. $拜瑪林製藥(BMRN.US)$ l — The pharma stock gained 11.4% after activist investor Elliott Investment Management built a stake i...
拜瑪林製藥股票討論區
Stocks making the biggest midday moves
$Datadog(DDOG.US)$
— Shares rallied more than 30% after the cloud company reported a third-quarter earnings and revenue beat before the bell. Datadog’s guidance for both earnings per share and revenue for the fourth quarter and the full year also exceeded expectations.
$拜瑪林製藥(BMRN.US)$
l — The pharma stock gained 11.4% after activist investor Elliott Investment Management built a stake i...
Moderna $Moderna(MRNA.US)$ , $Etsy Inc(ETSY.US)$ , Albemarle $美國雅保(ALB.US)$ , Aptiv $Aptiv PLC(APTV.US)$ , Biomarin $拜瑪林製藥(BMRN.US)$ , and Confluent $Confluent(CFLT.US)$ all hit new 52 week lows today
Here are more in...
Loading up the bags
本週短線操作
暫無評論